Medical News Today, August 2017
A common obstacle in the treatment of pancreatic cancer is drug resistance. However, new research has shown that curcumin - a compound that can be found in turmeric - can help to overcome the resistance to chemotherapy. Curcumin is the active compound found in plants such as turmeric, and more and more studies have been pointing to the therapeutic potential of the compound for various conditions, ranging from cancer to diabetes. Preclinical studies have suggested that the compound has various antioxidant, neuroprotective, anti-inflammatory, and anticarcinogenic properties. "By treating certain cells with small doses of curcumin, we were able to reverse the pathways that lead to chemoresistance," says Dr. Goel. "This is an important breakthrough that could lead to better prognosis and longer lives for patients with chemoresistant pancreatic cancer." Previous studies have shown that curcumin has preventative benefits, but to the authors' knowledge, this is the first study that shows the beneficial effect of the plant extract in combination with chemotherapy and its advantages in overcoming drug resistance.
Oxford University Press, December 2017
Over the past few decades, curcumin, a common food additive, has been identified as a potential anti-inflmmatory and anti-cancer compound. Curcumin is a phenolic compound extracted from the Curcuma longa plant, and was traditionally used as a spice for improving flavor and color into dishes of various Asian countries. Curcumin’s health benefits are not a new or surprising finding — the brightly colored compound has been used in Ayurvedic medicine for centuries for its potent anti-inflammatory and anti-tumor properties — but the fundamental mechanisms underlying its anti-cancer potential still remain an active area of interrogation. Intriguingly, curcumin has been shown to sensitize multiple cancers to chemotherapy drugs, and several recent studies have reported that curcumin is able to specifically target cancer stem cells. . As suggested by other groups, not only did we demonstrate that curcumin was able to enhance the sensitivity of gemcitabine in these resistant cells, we found that curcumin was also able to inhibit the growth of cancer stem cells. In our study, we also discovered that curcumin was regulating a class of non-coding RNA called “long non-coding RNAs” (lncRNAs). LncRNA is a relatively newly discovered type of non-coding RNA — RNA which does not make protein — found to be dysregulated in most cancers. We discovered that curcumin inhibits the expression of one of the most well-known lncRNA-based oncogenes, a gene that drives cancer, called PVT1. This lncRNA drives tumor progression through the regulation of another well-recognized oncogene, called EZH2. EZH2 is one of the oncogenes known to be involved in drug resistance and is identified to be a potential drug-able target. Though the generation of specific EZH2 inhibitors remains challenging, the findings from our study indicate that curcumin could be used to inhibit the expression of EZH2, as well as the non-coding RNA that regulates EZH2. Considering that curcumin is a commonly available health supplement, it presents itself as a non-toxic compound and incredibly cost-effective compound for the potential treatment of cancer patients.
Antibacterial activity of lemongrass ( Cymbopogon …
Antimicrobial resistance (AMR) is the ability of a microorganism (like bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it. As a result, standard treatments become ineffective, infections persist and may spread to others.